ClinicalTrials.gg
CompletedNCT04379336Updated Jan 25, 2022

BCG Vaccination for Healthcare Workers in COVID-19 Pandemic

A Phase 3 interventional study of Bacille Calmette-Guérin (BCG) and Placebo Comparator in COVID-19 and Sars-CoV2, sponsored by TASK Applied Science. Completed at 1 site in South Africa. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by TASK Applied Science · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing BCG Vaccine in COVID-19 — none open to participants now, 3 under way, 1 of them phase 3. BCG Vaccine · COVID-19.

Enrollment
6th of 14
1,000 · median 830
Started
2020
with 10 others
Phase 3
7 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
1 of 14
TASK Applied Science

Among the 14 studies testing BCG Vaccine in COVID-19, this one is the 6th largest by enrollment, is one of 11 that started in 2020, is one of 7 in phase 3, and was the 6th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 14 studies testing BCG Vaccine in COVID-19 is open now. The open studies under COVID-19, anywhere →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing BCG Vaccine in COVID-19 as a file.
02

Study summary

A novel betacoronavirus, SARS-CoV-2, is spreading rapidly throughout the world. A large epidemic in South Africa may overwhelm available hospital capacity and healthcare resources which would be worsened by absenteeism of healthcare workers and other frontline staff (HCW). Strategies to prevent morbidity and mortality of HCW are desperately needed to safeguard continuous patient care. Bacillus Calmette-Guérin (BCG) is a vaccine against tuberculosis (TB), with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, with reported morbidity and mortality reductions as high as 70%. We hypothesize that a BCG vaccination may reduce the morbidity and mortality of healthcare workers during the COVID-19 outbreak in South Africa.

Read the detailed description

Morbidity and mortality attributable to COVID-19 is devastating global health systems and economies. Bacillus Calmette Guérin (BCG) vaccination has been in use for many decades to prevent severe forms of tuberculosis in children. Studies have also shown a combination of improved long-term innate or trained immunity (through epigenetic reprogramming of myeloid cells) and adaptive responses after BCG vaccination, which leads to non-specific protective effects in adults. Observational studies have shown that countries with routine BCG vaccination programs have significantly less reported cases and deaths of COVID-19, but such studies are prone to significant bias and need confirmation. To date, in the absence of direct evidence, WHO does not recommend BCG for the prevention of COVID-19.

This project aims to investigate in a timely manner whether and why BCG-revaccination can reduce infection rate and/or disease severity in health care workers during the SARS-CoV-2 outbreak in South Africa. These objectives will be achieved with a blinded, randomised controlled trial of BCG revaccination versus placebo in exposed front-line staff in hospitals in Cape Town. Observations will include the rate of infection with COVID-19 as well as the occurrence of mild, moderate or severe ambulatory respiratory tract infections, hospitalisation, need for oxygen, mechanical ventilation or death. HIV-positive individuals will be excluded. Safety of the vaccines will be monitored. A secondary endpoint is the occurrence of latent or active tuberculosis. Initial sample size and follow-up duration is at least 500 workers and 52 weeks. Statistical analysis will be model-based and ongoing in real time with frequent interim analyses and optional increases of both sample size or observation time, based on the unforeseeable trajectory of the South African COVID-19 epidemic, available funds and recommendations of an independent data and safety monitoring board.

Given the immediate threat of the SARS-CoV-2 epidemic the trial has been designed as a pragmatic study with highly feasible endpoints that can be continuously measured. This allows for the most rapid identification of a beneficial outcome that would lead to immediate dissemination of the results, vaccination of the control group and outreach to the health authorities to consider BCG vaccination for all qualifying health care workers.

03

Conditions studied

  • COVID-19
  • Sars-CoV2

Browse trials for

Keywords

  • Blinded
  • Randomized controlled
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥18 years
  • HCW or other frontline staff currently in contact with, or anticipated to be in contact with, patients with SARS-CoV-2 infection.
  • Ability and willingness to provide .
  • Can be reached by mobile phone for follow-up

Exclusion criteria

Exclusion Criteria:

  • Known allergy to (components of) the BCG vaccine or serious reaction to prior BCG administration.
  • Known active tuberculosis or any other active or uncontrolled condition that, in the opinion of the investigator or designee, makes participation unsafe or makes it difficult to collect follow-up data over the study period.
  • -1 infection

    • NOTE: If evidence of recent HIV negative test is not available, rapid point-of-care testing will be undertaken as part of screening with a separate process.
  • Symptoms of respiratory tract infection which, in the opinion of the investigator or designee, is likely to interfere with the objectives of the study.
  • Known medical history of any of the following states:

    • Neutropenia (less than 500 neutrophils/mm3)
    • Lymphopenia (less than 400 lymphocytes/mm3)
    • Solid organ or bone marrow transplantation
    • Primary immunodeficiency
    • Active solid or non-solid or lymphoma within the prior two years
    • Pregnancy and breastfeeding
  • Current treatment with the following medications:

    • Chemotherapy
    • Anti-cytokine therapies
    • Current treatment with oral or intravenous defined as daily doses of 10mg prednisone or equivalent for longer than 3 months
    • Any experimental, unproven treatment against SARS-CoV-2 infection or COVID-19 including but not limited to chloroquine, hydroxychloroquine, remdesivir, lopinavir/ritonavir and interferon beta-1a.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,000 participants (actual)

Study arms

  • Experimental
    Bacille Calmette-Guérin (BCG)

    Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI \[Statens Serum Institut\], Danish strain 1331.

    Biological: Bacille Calmette-Guérin (BCG)

  • Placebo comparator
    Placebo

    The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.

    Other: Placebo Comparator

Interventions

  • BiologicalBCG VaccineStudies of BCG VaccineBCG Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BCG vaccine will be given intradermally in the upper arm after randomization.

    Also known as: BCG-Vaccin SSI [Statens Serum Institut], Danish strain 1331

  • OtherPlacebo Comparator

    Placebo injection will be given intradermally in the upper arm after randomization.

    Also known as: 0.9% Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Incidence of HCWs hospitalized due to COVID-19 per arm

    To compare the incidence of HCWs hospitalized due to COVID-19 per arm.

    Time frame: 52 weeks

Secondary outcomes

  1. Incidence of SARS-CoV-2 infection per arm

    To determine the incidence of SARS-CoV-2 infection in HCW by molecular or serological testing (as available) at entry, 10, 26 and/or 52 weeks.

    Time frame: 52 weeks

  2. Incidence of upper respiratory tract infections per arm

    To compare the incidence of symptoms of upper respiratory tract infection per arm.

    Time frame: 52 weeks

  3. Days of unplanned absenteeism due to COVID-19 or any reason per arm

    To compare the number of days of (unplanned) absenteeism because of documented SARS-CoV-2 infection, COVID-19 or any reason per arm.

    Time frame: 52 weeks

  4. Incidence of hospitalization for any reason per arm

    To compare the incidence of hospitalization of HCW for any reason per arm.

    Time frame: 52 weeks

  5. Incidence of intensive care unit admission per arm

    To compare the incidence of intensive care admission of HCW due to COVID-19 or any reason per arm.

    Time frame: 52 weeks

  6. Incidence of death per arm

    To compare the incidence of death of HCW due to COVID-19 or any reason per arm.

    Time frame: 52 weeks

  7. Prevalence of latent TB infection

    To describe the prevalence of latent TB infection as determined by interferon gamma release assay (IGRA) at enrolment and at week 52.

    Time frame: 52 weeks

  8. Incidence of active TB per arm

    To compare the incidence of active TB of HCW per arm.

    Time frame: 52 weeks

  9. Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm

    To compare the effect of latent TB infection on morbidity and mortality of HCW due to COVID-19 per arm. The risk of morbidity and mortality of latent TB infected individuals is not known, we will examine whether there is a higher risk of disease severity and poor outcomes in this group.

    Time frame: 52 weeks

  10. Incidence of treatment related adverse events

    To compare the incidence of grade 2 or higher adverse events and vaccination site reactions per arm.

    Time frame: 52 weeks

07

Study locations

1 site
  • TASK Foundation
    Cape Town, Western Cape 7500, South Africa
08

References and documents

Publications

  • Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens. Cell Host Microbe. 2019 Jan 9;25(1):13-26. doi: 10.1016/j.chom.2018.12.006. PubMed 30629914 ↗
  • Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42. doi: 10.1073/pnas.1202870109. Epub 2012 Sep 17. PubMed 22988082 ↗
  • Upton CM, van Wijk RC, Mockeliunas L, Simonsson USH, McHarry K, van den Hoogen G, Muller C, von Delft A, van der Westhuizen HM, van Crevel R, Walzl G, Baptista PM, Peter J, Diacon AH; BCG CORONA Consortium. Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. EClinicalMedicine. 2022 Jun;48:101414. doi: 10.1016/j.eclinm.2022.101414. Epub 2022 May 12. PubMed 35582122 ↗

Individual participant data

Plan to share: No — IPD will only be shared among researchers included in the protocol team at this stage.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jan 2022, 19 months.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
May 7, 2020
StartActual
May 4, 2020
Primary completionActual
Jan 2, 2022
CompletionActual
Jan 2, 2022
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04379336
Lead sponsor
TASK Applied Science
Responsible party
Sponsor
First posted
May 7, 2020
Start date
May 4, 2020
Primary completion
Jan 2, 2022
Completion
Jan 2, 2022
Last update
Jan 25, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion